Showing 1–25 of 39 · Asia-Pacific
FY2026 revenue A$51.6m (+27.0%); net margin 4.5%; net income A$2.3m.
Underlying EBITDA A$6.8m (+34%); A$20.6m cash, no debt.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
FY2026 revenue A$94.2m (+16.0%); net margin 9.6%; net income A$9.0m.
EBITDA A$14.9m (+14%); NPAT up 52%.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Listed (300676.SZ).
Latest full-year results not yet captured by HSH.
Parent Canon (7751.T) group FY2025 revenue ¥4.62tn (+2.5%); operating margin 9.8%; net income ¥332.1bn.
Medical unit: sales ¥580.6bn (+2.1%), operating profit ¥32.8bn (prior-year loss).
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Listed (099750.KQ).
Latest full-year results not yet captured by HSH.
Parent Fujifilm Holdings (4901.T) group FY2025 revenue ¥3.36tn (+5.0%); operating margin 10.4%; net income ¥276.7bn.
Group figures; Healthcare is one of several segments.
Listed (6702.T).
Latest full-year results not yet captured by HSH.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Listed (6965.T).
Latest full-year results not yet captured by HSH.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
FY2025 revenue ¥1.09tn (-3.6%); operating margin 4.6%; net income ¥30.3bn.
Continuing operations; returned to operating profit from a ¥64.0bn loss.
Listed (328130.KQ).
Latest full-year results not yet captured by HSH.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
FY2025 revenue RMB 33.28bn (-9.4%); net margin 25.4%; net income RMB 8.45bn.
Net profit fell 30.3%; operating profit not stated in summary.
Listed (6701.T).
Latest full-year results not yet captured by HSH.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Listed (6849.T).
Latest full-year results not yet captured by HSH.
Part of NTT (9432.T).
Latest full-year results not yet captured by HSH.
FY2025 revenue ¥1.01tn (+1.3%); operating margin 9.6%; net income ¥68.2bn.
Balance sheet figures not captured from release.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.